Loading
No description yet: the sentence for this tag has not been written. 4 records carry it: 4 roadmaps.
| Cancers | Other tags | ||||
|---|---|---|---|---|---|
Colorectal cancer roadmap: from the adenoma-carcinoma sequence and the first screening trials to total mesorectal excision, oxaliplatin, RAS testing, immunotherapy for mismatch repair-deficient disease, ctDNA-guided treatment and organ preservation Bowel cancer grows from a polyp over years, so removing the polyp prevents it. This roadmap follows the evidence from that discovery through the stool tests and scopes that built the screening programmes, the operation that changed rectal cancer, the chemotherapy and antibody era, immunotherapy that dissolves some tumours without surgery, and the unexplained rise in young adults, to 2032. | Colorectal cancer, Colon cancer, Rectal cancer | none | colorectal, gi, colorectal-evidence | ||
Gallbladder cancer roadmap: from a chance finding at gallstone surgery to a disease with its own trials Gallbladder cancer is usually found by accident when a gallbladder is removed for stones, and for most of its history the only treatment was a bigger operation. This roadmap follows the disease from the first cholecystectomy in 1882, through staging by depth and the borrowed chemotherapy standards of 2010 and 2019, to immunotherapy and HER2 drugs, and lists the trial readouts to watch to 2030. | Gallbladder cancer, Biliary tract cancer, Biliary tract cancer | none | gallbladder, biliary | ||
Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question Pancreatic cancer has had one operation since 1935 and a handful of chemotherapy drugs since 1997. This roadmap follows the evidence through FOLFIRINOX, chemotherapy before and after surgery, the first inherited-gene drug, the first drugs against the KRAS protein that drives nearly every tumour, personalised vaccines, and the surveillance and blood tests that might catch it earlier, to 2031. | Pancreatic ductal adenocarcinoma, Resectable pancreatic ductal adenocarcinoma, Borderline resectable pancreatic ductal adenocarcinoma | none | pancreatic, gi | ||
Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem Triple-negative breast cancer was named for what it lacks, the three receptors other breast cancers are treated through. This roadmap follows it from the receptor discoveries and the basal-like signature of 2000, through chemotherapy, platinum, PARP inhibitors, immunotherapy and antibody-drug conjugates, to the trials asking who can have less and who needs more, with registry dates to 2030. | Triple-negative breast cancer, HR-positive / HER2-negative breast cancer, HER2-positive breast cancer | none | tnbc, breast |